M Besenval

633 total citations
11 papers, 499 citations indexed

About

M Besenval is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, M Besenval has authored 11 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 2 papers in Pharmacology. Recurrent topics in M Besenval's work include Cancer Treatment and Pharmacology (8 papers), Lung Cancer Treatments and Mutations (4 papers) and Neutropenia and Cancer Infections (3 papers). M Besenval is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Lung Cancer Treatments and Mutations (4 papers) and Neutropenia and Cancer Infections (3 papers). M Besenval collaborates with scholars based in France, United States and Switzerland. M Besenval's co-authors include Anthony W. Tolcher, Dorothée Sémiond, Alain C. Mita, Eric K. Rowinsky, Leonel Ochoa, Muralidhar Beeram, Bahram Forouzesh, Amita Patnaik, Johann S. de Bono and Andrew Goetz and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

M Besenval

10 papers receiving 488 citations

Peers

M Besenval
L A Speicher United States
Nicoletta Staropoli Italy
J.-M. Nabholtz Canada
Jolien Van den Bossche Belgium
Haby Henary United States
A.-R. Hanauske Germany
G Mariani Italy
Peter Cheverton United Kingdom
Loreley Calvet France
Vincent A. de Weger Netherlands
L A Speicher United States
M Besenval
Citations per year, relative to M Besenval M Besenval (= 1×) peers L A Speicher

Countries citing papers authored by M Besenval

Since Specialization
Citations

This map shows the geographic impact of M Besenval's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Besenval with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Besenval more than expected).

Fields of papers citing papers by M Besenval

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Besenval. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Besenval. The network helps show where M Besenval may publish in the future.

Co-authorship network of co-authors of M Besenval

This figure shows the co-authorship network connecting the top 25 collaborators of M Besenval. A scholar is included among the top collaborators of M Besenval based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Besenval. M Besenval is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Mita, Alain C., Louis Denis, Eric K. Rowinsky, et al.. (2009). Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(2). 723–730. 260 indexed citations
2.
Zatloukal, Petr, Radj Gervais, Johan Vansteenkiste, et al.. (2008). Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(8). 894–901. 22 indexed citations
3.
Dièras, Véronique, Steven Limentani, Gilles Romieu, et al.. (2008). Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Annals of Oncology. 19(7). 1255–1260. 58 indexed citations
4.
Diéras, V., Vicente Valero, Steven Limentani, et al.. (2005). Multicenter, non-randomized phase II study with RPR109881 in taxane-exposed metastatic breast cancer (MBC) patients (pts): Final results. Journal of Clinical Oncology. 23(16_suppl). 565–565. 13 indexed citations
5.
Sessa, Cristiana, C. Cuvier, S. Caldiera, et al.. (2002). Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Annals of Oncology. 13(7). 1140–1150. 37 indexed citations
6.
Lortholary, Alain, Pauline Maillard, R. Delva, et al.. (2000). Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy. European Journal of Cancer. 36(14). 1773–1780. 10 indexed citations
7.
Gelmon, Karen A., Jean Latreille, Anthony W. Tolcher, et al.. (2000). Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 18(24). 4098–4108. 46 indexed citations
8.
Chevalier, Thierry Le, D. Brisgand, Jean Louis Pujol, et al.. (1996). [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].. PubMed. 83(5). 385–94. 7 indexed citations
9.
10.
Besenval, M, et al.. (1989). Safety and tolerance of Navelbine in phase I-II clinical studies.. PubMed. 16(2 Suppl 4). 37–40. 31 indexed citations
11.
Marty, M., et al.. (1989). Advances in vinca-alkaloids: Navelbine.. PubMed. 31(2). 77–84. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L A Speicher Breakdown of academic impact, for papers by Nicoletta Staropoli Breakdown of academic impact, for papers by J.-M. Nabholtz Breakdown of academic impact, for papers by Jolien Van den Bossche Breakdown of academic impact, for papers by Haby Henary Breakdown of academic impact, for papers by A.-R. Hanauske Breakdown of academic impact, for papers by G Mariani Breakdown of academic impact, for papers by Peter Cheverton Breakdown of academic impact, for papers by Loreley Calvet Breakdown of academic impact, for papers by Vincent A. de Weger
Rankless by CCL
2026